Processa Pharmaceuticals, Inc. Accounts Payable
Processa Pharmaceuticals, Inc. (PCSA) had Accounts Payable of $1.66 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-14
- 2026-06-30: Accounts Payable, Current $1.66M.
- 2026-03-31: Accounts Payable, Current $840.37K.
- 2025-12-31: Accounts Payable, Current $1.06M.
- 2025-09-30: Accounts Payable, Current $727.17K.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.66M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $840.37K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.06M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $727.17K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $785.75K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $552.56K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $880.88K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $711.71K 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $953.09K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $455.37K 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $311.62K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $346.30K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $239.02K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $316.71K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $327.55K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $311.07K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $648.10K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $316.09K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $218.91K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $354.98K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $287.88K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $177.02K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $320.69K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $427.45K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $73.37K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $93.22K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $75.61K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $64.86K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $143.35K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $283.06K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $292.10K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $80.02K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $251.40K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $104.88K 10-Q · filed 2018-05-21 | |
| 2017-12-31 | $50.69K 10-K/A · filed 2019-04-08 | |
| 2017-09-30 | $95.57K 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $91.19K 10-Q · filed 2017-10-04 | |
| 2017-03-31 | $179.32K 10-Q · filed 2017-10-04 | |
| 2016-12-31 | $14.59K 10-K · filed 2018-04-16 | $166.16K 10-K · filed 2017-09-25 |
| 2016-09-30 | $170.66K 10-Q · filed 2017-09-08 | |
| 2016-06-30 | $173.91K 10-Q · filed 2017-08-30 | |
| 2016-03-31 | $169.27K 10-Q · filed 2017-08-07 | |
| 2015-12-31 | $159.25K 10-K · filed 2017-09-25 | |
| 2015-09-30 | $190.73K 10-Q · filed 2015-12-01 | |
| 2015-06-30 | $218.79K 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $177.65K 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $153.93K 10-K · filed 2017-06-19 | $190.17K 10-K · filed 2015-04-14 |
| 2014-09-30 | $144.56K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $111.96K 10-Q · filed 2014-08-19 | |
| 2014-03-31 | $82.69K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $77.03K 10-K · filed 2015-04-14 | |
| 2013-09-30 | $101.39K 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $233.28K 10-Q/A · filed 2013-09-06 | |
| 2012-12-31 | $73.17K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |